Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 mg/ml - injection, emulsion - excipient ingredients: soya oil; glycerol; oleic acid; sodium hydroxide; water for injections; egg lecithin - fresofol 1% is a short-acting intravenous anaesthetic agent suitable for the induction and maintenance of general anaesthesia in adults and children aged three years and older. fresofol 1% has no analgesic properties. although the safety and efficacy of fresofol 1% in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. fresofol 1% may also be used in adults for the sedation of ventilated patients receiving intensive care, and for monitored conscious sedation for surgical and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; sodium metabisulfite; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium metabisulfite; sodium hydroxide; sodium chloride - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block